

Reportable ranges for antimicrobials and bacteria covered by AStar BC G– Kit (US). Dots indicate where MIC results and interpretations (when applicable) will be presented.

Antimicrobial class	Antimicrobial agent	<i>A. baumannii</i> complex	<i>C. freundii</i> complex	<i>C. koseri</i>	<i>E. cloacae</i> complex	<i>E. coli</i>	<i>K. aerogenes</i>	<i>K. oxytoca</i>	<i>K. pneumoniae</i> group	<i>M. morganii</i>	<i>P. mirabilis</i>	<i>P. vulgaris</i>	<i>S. marcescens</i>	<i>P. aeruginosa</i>
Penicillin	Ampicillin					•					•			
β-lactam combination agents	Ampicillin-sulbactam <sup>1</sup>	•		•		•		•	•	•	•	•		
β-lactam combination agents	Ceftazidime-tazobactam		•	•	•	•		•	•		•	•	•	•
β-lactam combination agents	Ceftazidime-avibactam <sup>2</sup>		•	•	•	•	•	•	•	•	•	•	•	•
β-lactam combination agents	Meropenem-vaborbactam <sup>3</sup>		•	•	•	•	•	•	•	•	•	•	•	•
β-lactam combination agents	Piperacillin-tazobactam <sup>4</sup>	•	•	•		•	•		•	•	•	•	•	
Cephalosporin	Cefazolin			•		•		•	•		•			
Cephalosporin	Cefepime		•	•	•	•	•	•	•		•	•	•	•
Cephalosporin	Cefotaxime		•	•	•	•		•	•		•	•	•	
Cephalosporin	Ceftriaxone		•	•	•	•	•	•	•		•	•	•	
Cephalosporin	Cefoxitin			•		•		•	•		•			
Cephalosporin	Cefuroxime			•		•		•	•		•			
Cephalosporin	Ceftazidime	•	•	•	•	•	•	•	•	•	•	•	•	
Monobactam	Aztreonam		•	•	•	•	•	•	•	•	•	•	•	•
Carbapenem	Ertapenem		•	•	•	•		•	•		•	•	•	
Carbapenem	Meropenem	•	•	•	•	•	•	•	•	•	•	•	•	•
Aminoglycoside	Gentamicin		•	•				•	•	•	•	•	•	
Aminoglycoside	Tobramycin		•	•	•	•	•	•	•		•	•		•
Aminoglycoside	Amikacin	•	•	•	•	•	•	•	•	•	•	•	•	
Tetracycline	Tigecycline		•	•	•	•	•	•	•				•	
Fluoroquinolone	Ciprofloxacin		•	•	•	•	•	•	•	•	•	•	•	•
Fluoroquinolone	Levofloxacin		•	•	•	•	•	•	•	•	•	•	•	•
Miscellaneous	Trimethoprim-sulfamethoxazole <sup>5</sup>		•	•	•	•	•	•	•	•		•		

<sup>1</sup> Ampicillin-sulbactam in the ratio 2:1

<sup>2</sup> For susceptibility testing purposes, the concentration of avibactam is fixed at 4 µg/mL

<sup>3</sup> For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 µg/mL

<sup>4</sup> For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 µg/mL

<sup>5</sup> Trimethoprim:sulfamethoxazole in the ratio 1:19

Antimicrobial reportable ranges for AST and FDA-recognized/approved clinical breakpoints, i.e. susceptible (S), intermediate (I), susceptible-dose dependent (SDD) and resistant (R).

Antimicrobial agent	ASTar BC G- Reportable range (µg/mL)	Organism Group	FDA-Recognized / Approved Breakpoints (µg/mL)		
			S	I/SDD	R
Amikacin	≤2 to ≥256	<i>A. baumannii</i> complex	≤8	16	≥32
	≤0.5 to ≥256 <sup>1</sup>	Enterobacterales	≤4	8	≥16
Ampicillin	≤1 to ≥128	Enterobacterales	≤8	16	≥32
Ampicillin-sulbactam	≤1 to ≥128 <sup>2</sup>	<i>A. baumannii</i> complex	≤8	16	32
		Enterobacterales			
Aztreonam	≤0.25 to ≥128 <sup>3</sup>	Enterobacterales	≤4	8	≥16
	≤0.5 to ≥128	<i>P. aeruginosa</i>	≤8	16	≥32
Cefazolin	≤0.25 to ≥32	Enterobacterales	≤2	4	≥8
Cefepime	≤0.25 to ≥128	Enterobacterales	≤2	4-8 <sup>4</sup>	≥16
		<i>P. aeruginosa</i>	≤8	16	≥32
Cefotaxime	≤0.25 to ≥16	Enterobacterales	≤1	2	≥4
Cefoxitin	≤1 to ≥128	Enterobacterales	≤4	8	≥16
Ceftazidime	≤0.5 to ≥128	<i>A. baumannii</i> complex	≤8	16	≥32
	≤0.25 to ≥128 <sup>5</sup>	Enterobacterales	≤4	8	≥16
Ceftazidime-avibactam	≤0.125 to ≥64 <sup>6</sup>	Enterobacterales	≤8	-	≥16
	≤0.125 to ≥64	<i>P. aeruginosa</i>			
Ceftolozane-tazobactam	≤0.25 to ≥64	Enterobacterales	≤2	4	≥8
		<i>P. aeruginosa</i>	≤4	8	≥16
Ceftriaxone	≤0.25 to ≥16	Enterobacterales	≤1	2	≥4
Cefuroxime	≤1 to ≥128	Enterobacterales	≤8	-	≥16
Ciprofloxacin	≤0.125 to ≥16	Enterobacterales	≤0.25	0.5	≥1
		<i>P. aeruginosa</i>	≤0.5	1	≥2
Ertapenem	≤0.06 to ≥16	Enterobacterales	≤0.5	1	≥2
Gentamicin	≤0.25 to ≥64	Enterobacterales	≤2	4	≥8
Levofloxacin	≤0.125 to ≥32	Enterobacterales	≤0.5	1	≥2
		<i>P. aeruginosa</i>	≤1	2	≥4
Meropenem	≤0.06 to ≥128	<i>A. baumannii</i> complex	≤2	4	≥8
	≤0.06 to ≥128 <sup>7</sup>	Enterobacterales	≤1	2	≥4
	≤0.06 to ≥128	<i>P. aeruginosa</i>	≤2	4	≥8
Meropenem-vaborbactam	≤0.25 to ≥64 <sup>8</sup>	Enterobacterales	≤4	8	≥16
Piperacillin-tazobactam	≤1 to ≥512	<i>A. baumannii</i> complex	≤16	32-64	≥128
	≤0.25 to ≥512 <sup>9</sup>	Enterobacterales	≤8	16	≥32
Tigecycline	≤0.03 to ≥32	Enterobacterales	≤2	4	≥8
Tobramycin	≤0.06 to ≥64 <sup>10</sup>	Enterobacterales	≤2	4	≥8
	≤0.125 to ≥64	<i>P. aeruginosa</i>	≤1	2	≥4
Trimethoprim-sulfamethoxazole	≤0.06 to ≥16 <sup>11</sup>	Enterobacterales	≤2	-	≥4

<sup>1</sup> AST Reportable range for Amikacin is ≤2 to ≥256 µg/mL for *C. koseri*, *E. coli*, *M. morgani* and *P. vulgaris*.

<sup>2</sup> AST Reportable range for Ampicillin-sulbactam is ≤2 to ≥128 µg/mL for *P. vulgaris*.

<sup>3</sup> AST Reportable range for Aztreonam is ≤0.5 to ≥128 µg/mL for *C. freundii* complex, *E. coli* and *M. morgani*.

<sup>4</sup> Interpretive category results for Cefepime/Enterobacterales are susceptible-dose dependent (SDD).

<sup>5</sup> AST Reportable range for Ceftazidime is ≤0.5 to ≥128 µg/mL for *C. freundii* complex, *C. koseri*, *K. aerogenes* and *M. morgani*.

<sup>6</sup> AST Reportable range for Ceftazidime-avibactam is ≤1 to ≥64 µg/mL for *E. coli*, *K. aerogenes*, *K. pneumoniae* group, *M. morgani* and *P. vulgaris*.

<sup>7</sup> AST Reportable range for Meropenem is ≤0.125 to ≥64 µg/mL for *E. cloacae* complex, *K. aerogenes*, *K. oxytoca*, *K. pneumoniae* group and *M. morgani*.

<sup>8</sup> AST Reportable range for Meropenem-vaborbactam is ≤0.5 to ≥64 µg/mL for *M. morgani* and *P. vulgaris*.

<sup>9</sup> AST Reportable range for Piperacillin-tazobactam is ≤1 to ≥512 µg/mL for *C. freundii* complex, *E. coli*, *K. aerogenes*, *K. pneumoniae* group and *M. morgani*.

<sup>10</sup> AST Reportable range for Tobramycin is ≤0.125 to ≥64 µg/mL for *K. aerogenes*, *K. oxytoca*, *K. pneumoniae* group and *P. vulgaris*.

<sup>11</sup> AST Reportable range for Trimethoprim-sulfamethoxazole is ≤0.25 to ≥16 µg/mL for *C. freundii* complex, *C. koseri* and *M. morgani*.